Scientists hunt for hidden antibodies in severe seizure disorders

NCT ID NCT04421846

Recruiting now Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen May 23, 2026 · Last updated Jun 16, 2026 · Updated 4 times

Summary

This study collects blood, spinal fluid, and brain tissue from 400 people with severe seizures (status epilepticus) or epilepsy linked to brain inflammation (dysimmune encephalitis), plus control patients. Researchers aim to find antibodies and markers of nerve cell death that could improve diagnosis and understanding of these serious conditions. Participants must be 2 years or older and enrolled in French social security.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STATUS EPILEPTICUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hôpital de la Pitié Salpêtrière
RECRUITING

Paris, 75013, France

Contact Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

DYSIMMUNE ENCEPHALOPATHY STATUS EPILEPTICUS

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

DYSIMMUNE ENCEPHALITIS